The global plasmid DNA manufacturing market size is expected to reach US$ 2.1 billion by 2030 from US$ 306.4 million in 2020 and is expected to grow at an impressive double-digit rate of 21.7% from 2021 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global plasmid DNA manufacturing Market for the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2020 is considered as the base year.
Crucial factors accountable for market growth are:
- Growing burden of cancer cases
- Growing prevalence of disease
- Growing geriatric population
- Heavy investments on technology and innovations
- Rising government expenditure on healthcare sector in emerging economies
- Rapid growth of the biopharmaceutical industry
- Growing popularity of gene therapy amongst the consumer/patients
We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1299
Report Highlights
- By product type, the viral vector segment led the global plasmid DNA manufacturing market with remarkable revenue share in 2020. The demand for the viral vector in the production of vaccines, cell therapies, and gene therapies is already very huge across the globe. The COVID-19 pandemic further boosted its increasing demand for the vaccine production.
- By application, the gene therapy segment led the global plasmid DNA manufacturing market with remarkable revenue share in 2020.This is because of the growing confidence of the people regarding the effectiveness, reliability, and safety of the gene therapies in the treatment of various chronic and genetic diseases.
- By disease, the cancer segment is expected to be the fastest-growing segment throughout the forecast period, owing to the increasing uses of the plasmid DNA in the development of various treatment therapies for the cancer
Market Dynamics
Drivers
The growing usage of plasmid DNA for the development of vaccines is fueling the demand. The plasmid DNA is extensively used for developing vaccines for diseases such as influenza, HIV, malaria, pathogens, and Ebola. The DNA vaccines are highly effective and hence, it is increasingly used, thereby fostering the consumption of plasmid DNA.
Restraints
Various risks related to gene therapies like mutagenesis may hamper the market growth. Further, stringent government regulations and high costs involved may restrict the adoption of gene therapies. These factors have an adverse effect on the market.
Opportunities
Growing investments and innovations in the biopharmaceutical industry to develop innovative manufacturing technologies to increase the commercial production output of the plasmid DNA may have a big impact on the market during the forecast period.
Challenges
Lack of adequate infrastructure and financial limitations poses a challenge to carry on the smooth functioning of the research and developmental activities in the field of plasmid DNA manufacturing.
Regional Snapshots
North America is the leading plasmid DNA manufacturing market. The growing investments in the development of new biopharmaceutical medicines are resulting in rise in the number of contract manufacturers in the region. Moreover, US hold the maximum intellectual property copyrights for majority of the newly developed medicines. The higher adoption rate of advanced healthcare services coupled with growing preferences for gene and cell therapies among the population is a major factor that propelled the demand for the plasmid DNA manufacturing market in North America. The continuous research and development activities towards the development of new biopharma medicines are expected to foster market growth in the forthcoming years. Along with the growth of the contract manufacturers, North America is also hub for the numerous contract research organizations that facilitates development of new medicines.
Asia Pacific is expected to witness highest growth rate throughout the forecast period owing to the growing manufacturing of plasmid DNA in the region. The world’s largest contract manufacturing company, GenScript started its operation in China by setting up a plasmid and virus facility in December 2019. This is a major development in the Asia Pacific plasmid DNA manufacturing market. Furthermore, the presence of Biocon in India and Samsung Biologics in South Korea are witnessing spike in their sales in the past few years. These factors are expected to boost the plasmid DNA manufacturing market in the region.
Why should you invest in this report?
If you are aiming to enter the global plasmid DNA manufacturing market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for plasmid DNA manufacturing are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Key Players
The major players in the market are VGXI, Inc., Vigene Biosciences, Luminous Biosciences, Akron Biotech, Aldevron, Cobra Biologics & Pharmaceutical Services, Plasmidfactory GmbH, Nature Technology Corporation, Delphi Genetics, JAFRAL Ltd.
Market Segmentation:
By Product
- Viral Vectors
- Plasmid DNA
- Non-Viral
- Electroporation
- Lipid/Polymer
- Nanoparticles
- Others
By Application
- Gene Therapy
- DNA Vaccines
- Immunotherapy
- Others
By Disease
- Infectious Disease
- Genetic Disorder
- Cancer
Regional Analysis:
The geographical analysis of the global plasmid DNA manufacturing market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American market is again segmented into the US, Canada, and Mexico. Coming to the European market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global plasmid DNA manufacturing Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global plasmid DNA manufacturing market in 2030?
- What is the expected CAGR for the plasmid DNA manufacturing market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global plasmid DNA manufacturing market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Plasmid DNA Manufacturing Market, By Product
7.1. Plasmid DNA Manufacturing Market, by Product Type, 2021-2030
7.1.1. Viral Vectors
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Plasmid DNA
7.1.2.1. Market Revenue and Forecast (2019-2030)
7.1.3. Non-Viral
7.1.3.1. Market Revenue and Forecast (2019-2030)
7.1.4. Electroporation
7.1.4.1. Market Revenue and Forecast (2019-2030)
7.1.5. Lipid/Polymer
7.1.5.1. Market Revenue and Forecast (2019-2030)
7.1.6. Nanoparticles
7.1.6.1. Market Revenue and Forecast (2019-2030)
7.1.7. Others
7.1.7.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Plasmid DNA Manufacturing Market, By Application
8.1. Plasmid DNA Manufacturing Market, by Application, 2021-2030
8.1.1. Gene Therapy
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Immunotherapy
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Plasmid DNA Manufacturing Market, By Disease
9.1. Plasmid DNA Manufacturing Market, by Disease, 2021-2030
9.1.1. Infectious Disease
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Genetic Disorder
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Cancer
9.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.3. Market Revenue and Forecast, by Disease (2019-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.6.3. Market Revenue and Forecast, by Disease (2019-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.7.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.6.3. Market Revenue and Forecast, by Disease (2019-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.7.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.6.3. Market Revenue and Forecast, by Disease (2019-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.7.3. Market Revenue and Forecast, by Disease (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.3. Market Revenue and Forecast, by Disease (2019-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.4.3. Market Revenue and Forecast, by Disease (2019-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.5.3. Market Revenue and Forecast, by Disease (2019-2030)
Chapter 11. Company Profiles
11.1. VGXI, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Akron Biotech
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Cobra Biologics & Pharmaceutical Services
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Aldevron
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Plasmidfactory GmbH
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Vigene Biosciences
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Luminous Biosciences
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Nature Technology Corporation
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Delphi Genetics
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. JAFRAL Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1299
About Us:
Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and among different ventures present globally.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
0 Comments